Supernus Pharmaceuticals (SUPN) Payables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Payables data on file, last reported at $101.2 million in Q1 2026.

• On a quarterly basis, Payables rose 31.67% year-over-year to $101.2 million in Q1 2026; TTM through Mar 2026 was $101.2 million, a 31.67% increase from a year earlier, with the FY2025 full-year figure at $107.8 million, up 41.19% from the prior year.
• Payables for Q1 2026 stood at $101.2 million, down from $107.8 million in the prior quarter.
• Over the last five years, Payables for SUPN reached as high as $498.3 million in Q4 2022 and fell as low as $75.8 million in Q3 2024.
• Historically, Payables has averaged $139.0 million across 5 years, with a median of $86.4 million in 2024.
• On a YoY basis, Payables climbed as much as 456.67% in 2023 and fell as far as 84.03% in 2023.
• Year by year, Payables stood at $498.3 million in 2022, then plunged by 84.03% to $79.6 million in 2023, then slipped by 4.04% to $76.4 million in 2024, then soared by 41.19% to $107.8 million in 2025, then decreased by 6.08% to $101.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $101.2 million in Q1 2026, $107.8 million in Q4 2025, and $108.6 million in Q3 2025.